An instrument developed by US-based InLight Solutions can be used to screen patients for Type 2 diabetes without the use of invasive techniques.
The Scout instrument, as the system is called, employs fluorescence spectroscopy to noninvasively measure advanced glycation endproducts (AGEs) in the dermis of a subject’s forearm.
The concentration of AGEs in the dermis is an excellent indicator of cumulative hyperglycemic exposure and is highly correlated with the development of diabetes complications, according to InLight.
The accurate and reproducible (5% inter-day coefficient of variation) Scout measurement can also be made anytime of day because fasting is not required.
Simpler to perform than a blood pressure test, it takes less than 60 seconds to produce a quantitative result.